324 related articles for article (PubMed ID: 32482307)
1. PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias.
Fritz C; Portwood SM; Przespolewski A; Wang ES
Blood Rev; 2021 Jan; 45():100696. PubMed ID: 32482307
[TBL] [Abstract][Full Text] [Related]
2. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
[TBL] [Abstract][Full Text] [Related]
3. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Turk AA; Wisinski KB
Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
[TBL] [Abstract][Full Text] [Related]
4. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
5.
Molenaar RJ; Radivoyevitch T; Nagata Y; Khurshed M; Przychodzen B; Makishima H; Xu M; Bleeker FE; Wilmink JW; Carraway HE; Mukherjee S; Sekeres MA; van Noorden CJF; Maciejewski JP
Clin Cancer Res; 2018 Apr; 24(7):1705-1715. PubMed ID: 29339439
[No Abstract] [Full Text] [Related]
6. Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors.
Esposito MT; Zhao L; Fung TK; Rane JK; Wilson A; Martin N; Gil J; Leung AY; Ashworth A; So CW
Nat Med; 2015 Dec; 21(12):1481-90. PubMed ID: 26594843
[TBL] [Abstract][Full Text] [Related]
7. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
8. Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.
Sulai NH; Tan AR
Clin Adv Hematol Oncol; 2018 Jul; 16(7):491-501. PubMed ID: 30067621
[TBL] [Abstract][Full Text] [Related]
9. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
10. Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders.
Faraoni I; Giansanti M; Voso MT; Lo-Coco F; Graziani G
Biochem Pharmacol; 2019 Sep; 167():133-148. PubMed ID: 31028744
[TBL] [Abstract][Full Text] [Related]
11. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
[No Abstract] [Full Text] [Related]
12. Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD.
Dellomo AJ; Baer MR; Rassool FV
Cancer Lett; 2019 Jul; 454():171-178. PubMed ID: 30953707
[TBL] [Abstract][Full Text] [Related]
13. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Wang L; Wang Q; Xu Y; Cui M; Han L
Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
[TBL] [Abstract][Full Text] [Related]
14. Resurrection of PARP Inhibitors in Breast Cancer.
Lyons TG; Robson ME
J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424
[TBL] [Abstract][Full Text] [Related]
15. In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2.
Gbyli R; Song Y; Liu W; Gao Y; Biancon G; Chandhok NS; Wang X; Fu X; Patel A; Sundaram R; Tebaldi T; Mamillapalli P; Zeidan AM; Flavell RA; Prebet T; Bindra RS; Halene S
Leukemia; 2022 May; 36(5):1313-1323. PubMed ID: 35273342
[TBL] [Abstract][Full Text] [Related]
16. High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects.
Li X; Li C; Jin J; Wang J; Huang J; Ma Z; Huang X; He X; Zhou Y; Xu Y; Yu M; Huang S; Yan X; Li F; Pan J; Wang Y; Yu Y; Jin J
EBioMedicine; 2018 Dec; 38():47-56. PubMed ID: 30472087
[TBL] [Abstract][Full Text] [Related]
17. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogene.
Wang L; Cai W; Zhang W; Chen X; Dong W; Tang D; Zhang Y; Ji C; Zhang M
Oncotarget; 2015 Sep; 6(29):27490-504. PubMed ID: 26314963
[TBL] [Abstract][Full Text] [Related]
19. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
Onstad M; Coleman RL; Westin SN
Drugs; 2020 Oct; 80(15):1525-1535. PubMed ID: 32852746
[TBL] [Abstract][Full Text] [Related]
20. PARP and PARG inhibitors in cancer treatment.
Slade D
Genes Dev; 2020 Mar; 34(5-6):360-394. PubMed ID: 32029455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
